Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EA 2353

Next Previous
X
Search
Drug Profile

EA 2353

Alternative Names: EA-2353

Latest Information Update: 03 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Endogena Therapeutics
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinitis pigmentosa
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Retinitis pigmentosa

Most Recent Events

  • 10 Oct 2024 Endogena Therapeutics terminated a phase I/II trial for Retinitis pigmentosa due to a corporate decision by the sponsor, not because of any safety concerns related to EA-2353 (Intravitreous, Injection) (NCT05392751)
  • 04 May 2023 Endogena Therapeutics completes enrolment in phase I/II trial for Retinitis pigmentosa in the US
  • 06 Feb 2023 EA 2353 receives Fast Track designation for Retinitis pigmentosa [Intravitreous,Injection] in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top